SEONGNAM, South Korea, Sept. 7, 2020 /PRNewswire/ -- Bridge Biotherapeutics (288330 KQ) announced that the company's board of directors approved the issuance of new shares through a 2:1 bonus issue on September 7. Since Bridge Biotherapeutic's KOSDAQ listing in December 2019, the company...
from PR Newswire: https://ift.tt/3m1o7xq
No comments:
Post a Comment